News

Zorevunersen continues to show durable reductions in seizure frequency — alongside gains in cognition, behavior, and day-to-day functioning — in children and adolescents followed for up to three years. The investigational therapy targets the genetic cause of Dravet syndrome. The findings come from two long-term extension studies that followed…

A Phase 3 clinical trial testing the therapy candidate zorevunersen for Dravet syndrome is now recruiting children who still experience seizures despite being on stable treatment with antiseizure medications. The study, dubbed EMPEROR (NCT06872125), is open to pediatric patients ages 2 to 17. Enrollment is ongoing at…

Daily treatment with Fycompa (perampanel), on top of standard medications, was safe and reduced seizure frequency for children with Dravet syndrome whose seizures had not been previously controlled with other therapies, according to an observational study in China. Fycompa’s benefits were observed in children of all ages, including…

June is Dravet Syndrome Awareness Month in the U.S., and the Dravet Syndrome Foundation is spearheading efforts to raise funds and spread the word about this rare type of epilepsy. “By raising awareness of Dravet syndrome, our community can increase knowledge in the general public, improve early diagnosis,…

Praxis Precision Medicines is gearing up to launch a clinical trial of its experimental anti-seizure therapy relutrigine in people with Dravet syndrome and other disorders that cause seizures in childhood, collectively known as developmental and epileptic encephalopathies (DEEs). According to a corporate presentation, the study, dubbed EMERALD,…

Long-term use of the approved Dravet syndrome therapy Fintepla (fenfluramine) safely and consistently reduces seizure frequency in children and young adults with the genetic condition, according to the final analysis of an open-label extension of a Phase 3 clinical trial. Dubbed ZX008-1503 (NCT02823145), the international long-term study tracked…

Stoke Therapeutics and Biogen are teaming up for the further development and potential commercialization of zorevunersen, an experimental treatment for Dravet syndrome that’s moving into late-stage clinical testing. “With Biogen’s deep experience in neurology and track record of success in commercializing high-value disease-modifying medicines for…

Stoke Therapeutics plans to launch a Phase 3 study this year to evaluate zorevunersen, a potential disease-modifying therapy for Dravet syndrome. The trial, dubbed EMPEROR, which was announced after an agreement was reached with regulators in the U.S., European Union, and Japan, will test if a year of…

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to relutrigine, a treatment candidate for Dravet syndrome that’s being developed by Praxis Precision Medicines. The therapy aims to reduce seizures in children with epileptic disorders such as Dravet. “We are thrilled to have been…

Health-related quality of life is low for parents of children with Dravet syndrome relative to the general public in Sweden, with higher levels of anxiety, depression, and other mental health challenges, along with poorer sleep, a study found. Higher levels of anxiety were reported among these women than among…